Multipurpose prevention technologies and their potential interaction with vaccines. Robin Shattock
|
|
- Lynne Gibson
- 7 years ago
- Views:
Transcription
1 Multipurpose prevention technologies and their potential interaction with vaccines Robin Shattock
2 Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/coital) Exposure (pre-coital/coital) After infection Male circumcision Oral pre exposure prophylaxis (daily PrEP) Topical PrEP (daily gels or intra-vaginal rings (microbicides) Preventive HIV Vaccines Preventative STD vaccines Oral pre exposure prophylaxis (intermittent PrEP) Coitally dependent topical PrEP (microbicides) Oral post exposure prophylaxis (PEP) Anti-retroviral therapy Immediate treatment of positive partners in discordant couples Treatment for prevention in all who test positive for HIV (T4P)
3 Time to consider a combination approach to biomedical interventions Possible biomedical prevention combinations: Combined use of oral PREP and microbicides for intermittent dosing optimal systemic and local drug levels (steady state and bolus) PrEP (oral, topical) for women combined with circumcision + oral PrEP for men T4P combined with ARV PrEP (microbicide or oral for women, oral for MSM) for the HIV-negative partner. HIV vaccines plus ARV PrEP specific considerations HIV vaccines plus T4P specific considerations HIV vaccines plus other STD vaccines
4 Lessons might be learned from the Thai RV144 vaccine trial The vaccine appeared most effective (60% reduction) at 1 year post vaccination Infection may be reflective of suboptimal immune responses (correlates analysis) or exposure to a higher and/or more frequent infectious challenge Revaccination (annual/biannual) likely required to have a significant impact on incidence (Hontelez et al Vaccine June 2011) Co-implementation of PrEP (oral, microbicides) might provide conditions that could significantly increase vaccine efficacy This hypothesis could be explored future ALVAC-protein primeboost trials.
5 How might (VaccPrEP) deliver better protection? Providing protection during the immunization period Reducing infectious challenge and primary foci of infection Increase eclipse phase prior to systemic viral dissemination providing an extended opportunity for adaptive immunity to respond Boosting local immunity (virus/antigen) Converting high risk challenge to low risk challenge (RV144) Coverage between potential re-vaccination campaigns as immunity wanes Providing better virological control in combination with immediate ART with potential for reduction/elimination of reservoirs
6 Can vaccine candidates be coformulated with microbicides?
7 Can VaccPrEP provide better protection than vaccine or PrEP alone 1% tenofovir gel A B D = IN (intranasal) immunization = IM (intramuscular) immunization = Challenge in presence of 1% tenofovir gel = Challenge in the absence of microbicide = Assess systemic and local immunity
8 Can biomedical combinations be tested in clinical trials? Design 1, PrEP (oral or microbicide) assumed not to be in general use. (closing window of opportunity for use of placebo PrEP) A 4 arm study: 1. Placebo (placebo vaccine + placebo PrEP) 2. PrEP (placebo vaccine + PrEP), 3. Vaccine (vaccine + placebo PrEP), 4. VaccPrEp (vaccine+ PrEP) Requires infection to demonstrate direct benefit of vaccination with or without PrEP (fewer infections needed when synergy is present). Potential for adaptive design: assess relative ranking of active arms test for superiority among active arms test for interaction (synergy) of the combination eliminate regimes not better than placebo introduce vaccine boost if needed.
9 Can biomedical combinations be tested in clinical trials? Design 2: PrEP reduces risk of HIV acquisition (oral 44-73%, microbicide 39%) assumes PrEP is available to all participants? Two-arm study: PrEP alone Vaccine + PrEP (VaccPrEP) Requires 30 to 60 incident infections to assess the additional benefit of vaccination on risk of infection and setpoint viral load. Main challenge, PrEP as active control arm will reduce incidence and increase trial size Superiority of VaccPREP does not imply vaccine alone is efficacious Lack of superiority does not imply vaccine alone is ineffective (potential antagonism). Excler JL, et al AIDS Res Hum Retroviruses Dec 16.
10 Potential challenges to combination trials Increased sample size, trial complexity and cost Additional visits for safety, HIV testing etc Risk compensation and adherence may vary according to perceived efficacy of the individual components of any combination Issue of informed choice become more complex Open-label trials may be the best way to assess concerns about risk compensation while learning about implementation.
11 Co-implementation of other STD vaccine Similar target groups Similar routes of transmission Significant shortfall in funding STD vaccines Technological advantages in HIV vaccine development could provide significant gains for development of other STD vaccines No vaccines Chlamydia (C. trachomatis)* Chancroid (Haemophilus ducreyi)* Gonorrhea (Neisseria gonorrhoeae)* Syphilis (Treponema pallidum)* Trichomoniasis (Trichomonas vaginalis)* Hepatits C Virus Herpes Simplex virus* Existing Vaccines Human Papilloma Virus Hepatits B Virus * Associated with increased risk of HIV acquisition Potential complications Antigenic competition and immuno-dominance Increased activation or recruitment of CD4 cells to mucosal surfaces might enhance HIV acquisition Negative impact on HIV vaccine efficacy
12 Summary Can vaccine candidates be co-formulated with microbicides: Yes Can mucosal exposure to virus in the context of PrEP lead to immune response: indicated in animals Does vaginal vaccination modify mucosal immunity to HIV: indicated in animals, yet to be tested in humans Will VaccPrEP provide better protection than PrEP alone?: indicated in animal models Can combination prevention be tested in human trials: Yes
13 Conclusions A limited window may exist for placebo (PrEP) controlled trials ARV PrEP combined with vaccines may create lower-risk conditions making a partially efficacious vaccine a viable option Additive or synergistic effects will stimulate incremental reductions in HIV incidence This in turn will raise the bar of evidence required for new approaches (cost-effectiveness and population impact) in RCT Decreasing incidence will necessitate larger and more costly trials with an increased emphasis on adaptive design Placing an intrinsic value on high incidence cohorts and predictors of vaccine efficacy.
14 Pathway to reversing the epidemic Seeing prevention research/funding as a continuum Circumcision Treatment 4 prevention ARV PrEP (oral, microbicide) Partially effective HIV vaccine STD vaccines A combined research strategy for biomedical interventions is likely to provide the fastest, most tangible impact on HIV transmission HIV incidence highly effective HIV vaccine Behavioral and structural interventions Science. 2011;333:42-3
HPTN 073: Black MSM Open-Label PrEP Demonstration Project
HPTN 073: Black MSM Open-Label PrEP Demonstration Project Overview HIV Epidemiology in the U.S. Overview of PrEP Overview of HPTN HPTN 061 HPTN 073 ARV Drug Resistance Conclusions Questions and Answers
More informationHIV Guidelines. New Strategies.
HIV Guidelines. New Strategies. Santiago Moreno Hospital Universitario Ramón y Cajal Madrid HIV Guidelines. New Strategies. Outline HIV Guidelines What is new? New strategies Treatment as Prevention HIV
More informationThe Basics of Drug Resistance:
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?
More informationCondoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers
Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers James Wilton Coordinator, Biomedical Science of HIV Prevention
More informationTOOLS, TRENDS AND NEW TECHNOLOGIES IN HIV PREVENTION
TOOLS, TRENDS AND NEW TECHNOLOGIES IN HIV PREVENTION Introduction In recent years, prevention has moved to the top of the global HIV and AIDS agenda. Michel Sidibé, Executive Director of UNAIDS, recently
More informationFrequently Asked Questions (FAQs)
Frequently Asked Questions (FAQs) Research Rationale 1. What does PrEP stand for? There is scientific evidence that antiretroviral (anti-hiv) medications may be able to play an important role in reducing
More informationProject AWARE Study Overview. Lisa Metsch, PhD Grant Colfax, MD Dan Feaster, PhD
Project AWARE Study Overview Lisa Metsch, PhD Grant Colfax, MD Dan Feaster, PhD January 9, 2012 Two Testing Strategies Evaluated in 2-arm RCT On-site HIV rapid testing (via fingerstick) with brief participant-tailored
More informationPre-exposure prophylaxis (PrEP)
FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.
More informationThe use of ARVs in HIV prevention and the case for optimizing the preventive impact of ART?
World Health Organization brief on antiretroviral treatment (ART) in HIV and TB prevention. Date: January 2011 This brief is intended as an introduction for WHO staff to the HIV and TB preventive benefit
More informationResponse to HIV/AIDS in Brazil, public health system strengthening and programmatic integration
Response to HIV/AIDS in Brazil, public health system strengthening and programmatic integration Fábio Mesquita Director STI, Aids and Viral Hepatitis Department Secretariat for Health Surveillance Ministry
More informationViral load testing. medical monitoring: viral load testing: 1
medical monitoring: viral load testing: 1 medical monitoring: viral load testing Viral load testing medical monitoring: viral load testing: 2 Slide 1 Viral load The viral load test measures HIV in the
More informationThe Botswana Combination Prevention Project (BCPP)
The Botswana Combination Prevention Project (BCPP) The Next Phase of HIV Prevention in Botswana A collaboration between MoH CDC-Botswana, HSPH-BHP Presenter: M.J. Makhema NAC 4 th September 2012 Mashi
More informationTHIS IS AN OFFICIAL NH DHHS HEALTH ALERT
THIS IS AN OFFICIAL NH DHHS HEALTH ALERT Distributed by the NH Health Alert Network Health.Alert@nh.gov August 13, 2015 1400 EDT (2:00 PM EDT) NH-HAN 20150813 Updated Centers for Disease Control (CDC)
More informationHIV/AIDS Prevention and Care
HIV/AIDS Prevention and Care Nancy S. Padian, PhD, MPH Professor, Obstetrics, Gynecology & Reproductive Sciences Associate Director for Research, Global Health Sciences and AIDS Research Institute: University
More informationCalifornia Guidelines for STD Screening and Treatment in Pregnancy
California Guidelines for STD Screening and Treatment in Pregnancy These guidelines were developed by the California Department of Public Health (CDPH) Sexually Transmitted Diseases (STD) Control Branch
More informationSummary of infectious disease epidemiology course
Summary of infectious disease epidemiology course Mads Kamper-Jørgensen Associate professor, University of Copenhagen, maka@sund.ku.dk Public health science 3 December 2013 Slide number 1 Aim Possess knowledge
More informationSYNDROMIC CASE MANAGEMENT OF RTIs Advantages, Limitations, Optimization
WHO COLLABORATING CENTRE FOR RESEARCH IN HUMAN REPRODUCTION Hôpitaux Universitaires de Genève SYNDROMIC CASE MANAGEMENT OF RTIs Advantages, Limitations, Optimization Dr SALONEY NAZEER Department of Gynaecology
More informationTREATMENT OF STI CONTACTS
This decision support tool is effective as of October 2014. For more information or to provide feedback on this or any other decision support tool, email certifiedpractice@crnbc.ca TREATMENT OF STI CONTACTS
More informationHIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline
HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline Background... 2 Screening... 2 Recommendations... 2 Ordering and consent... 2 Indications for Periodic HIV Screening...
More informationFrequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013
Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013 On July 16, 2012, the Food and Drug Administration (FDA) approved
More informationPublic Health and Future Access Group. Recommendations
Public Health and Future Access Group Recommendations Public Health and Future Access Working Group Dr. Catherine Hankins (Chair) Ms. Chutima Akaleephan Dr. Robert Chen Dr. Joseph Chiu Dr. Suwat Chariyalertsak
More informationEffective Integration of STI & HIV Prevention Programs
Effective Integration of STI & HIV Prevention Programs Jeanne Marrazzo, MD, MPH University of Washington, Seattle September 27, 2013 Key Points STIs are really common among those at highest risk of HIV
More informationChanges in the 2010 STD Treatment Guidelines: What Adolescent Health Care Providers Should Know February 2011
Changes in the 2010 STD Treatment Guidelines: What Adolescent Health Care Providers Should Know February 2011 Gale Burstein, MD, MPH, FAAP, FSAHM 1 Amanda Jacobs, MD, FAAP, 2 Dmitry Kissin, MD, MPH, 3
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationSCREENING FOR SEXUALLY TRANSMITTED INFECTIONS
SCREENING FOR SEXUALLY TRANSMITTED INFECTIONS Take history:- History of presenting problem Full sexual history (refer to guideline on sexual history taking) Relevant past medical history, including previous
More informationWilliam Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016
William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016 Advisory Committee on Immunization Practices (ACIP) The recommendations to be discussed are primarily those of the ACIP composed of 15
More informationGLOBAL OVERVIEW OF ANTIMICROBIAL RESISTANCE STD AGENTS
GLOBAL OVERVIEW OF ANTIMICROBIAL RESISTANCE STD AGENTS IN Dr.P.Bhalla Director Professor and Head Dept. of Microbiology Maulana Azad Medical College New Delhi, INDIA STDs & RTIs l HIV l Gonococcal infections/
More informationClinical Infectious Diseases Advance Access published September 1, 2015
Clinical Infectious Diseases Advance Access published September 1, 2015 1 No New HIV Infections with Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting Jonathan E. Volk 1, Julia
More informationPower to Detect the Effects of HIV Vaccination in Repeated Low-Dose Challenge Experiments
BRIEF REPORT Power to Detect the Effects of HIV Vaccination in Repeated Low-Dose Challenge Experiments Michael G. Hudgens, 1 Peter B. Gilbert, 2 John R. Mascola, 3 Chih-Da Wu, 1 Dan H. Barouch, 4 and Steven
More informationCondoms for the prevention of HIV and STI transmission
FACTSHEET Condoms for the prevention of HIV and STI transmission Summary Condoms are physical barriers that can reduce the risk of a sexual exposure to HIV and sexually transmitted infections (STIs). They
More informationIn the wake of the 13th international
STDs, Viral Load, Circumcision, and the Transmission of HIV Thomas C. Quinn, md Professor of Medicine, International Health, Molecular Biology and Immunology Johns Hopkins University Summary by Tim Horn
More informationProspects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS
Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates
More informationOutpatient/Ambulatory Health Services
Outpatient/Ambulatory Health Services Service Definition Outpatient/ambulatory medical care includes the provision of professional diagnostic and therapeutic services rendered by a physician, physician
More information2014 CDC Treatment Guidelines for STDs What s New, What s Important, What s Essential. STD Treatment Guidelines. How are the guidelines prepared?
2014 CDC Treatment Guidelines for STDs What s New, What s Important, What s Essential Bradley Stoner, MD, PhD Associate Professor, Washington University School of Medicine Medical Director, St. Louis STD/HIV
More informationSCIENCE AND TECHNOLOGY AS UGANDA AND THE SEARCH FOR AN AIDS VACCINE
SCIENCE AND TECHNOLOGY AS A DEVELOPMENT STRATEGY: UGANDA AND THE SEARCH FOR AN AIDS VACCINE Dr. David Kihumuro Apuuli Director General Uganda AIDS Commission Kampala, Uganda Ottawa, Ontario, Canada October
More informationTuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
More informationUnderstanding the HIV Care Continuum
Understanding the HIV Care Continuum Overview Recent scientific advances have shown that antiretroviral therapy (ART) not only preserves the health of people living with HIV, but also dramatically lowers
More informationThe public health approach to STD control
The public health approach to STD control WORLD BANK UNAIDS Technical Update UNAIDS Best Practice Collection At a Glance & There is a strong link between sexually transmitted diseases (STDs) and the sexual
More informationUp to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
More informationSEXUALLY TRANSMITTED INFECTIONS (STIs)
SEXUALLY TRANSMITTED INFECTIONS (STIs) The importance of a renewed commitment to STI prevention and control in achieving global sexual and reproductive health STIs: LARGE BURDEN AND SERIOUS CONSEQUENCES
More informationENHANCING ADOLESCENT SEXUAL HEALTH
ENHANCING ADOLESCENT SEXUAL HEALTH SERVICES BY CREATING AN ADOLESCENT MEDICAL HOME Gale R. Burstein, MD, MPH, FAAP, FSAHM Commissioner, Erie County Department of Health, Associate Clinical Professor, SUNY
More informationHPV Vaccines. What is HPV? Can a vaccine help prevent HPV?
What is HPV? HPV Vaccines HPV stands for human papilloma virus. HPVs are a group of more than 150 related viruses. Each HPV virus in the group is given a number, and is called an HPV type (for instance,
More informationScience addressing drugs and HIV: State of the Art. Vienna
Science addressing drugs and HIV: State of the Art 2 nd Scientific Statement: March 2016 Vienna Context In March 2014, UNODC organized within the frame of the High-level Review of the 57 th session of
More informationThe Contribution of Traditional Medicine in Treatment and Care in HIV/AIDS- The THETA Experience in Uganda
The Contribution of Traditional Medicine in Treatment and Care in HIV/AIDS- The THETA Experience in Uganda THETA background information THETA is an acronym that stands for: Traditional and modern Health
More informationWhen an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
More informationSpecial Considerations
Special Considerations Women and cart to Treatment What is medication adherence? taking medication exactly the way it is prescribed by the doctor taking the right amount of medication at the right time
More informationHIV Prevention Through Early Detection and Treatment of Other Sexually Transmitted Diseases United States
July 31, 1998 / Vol. 47 / No. RR-12 TM Recommendations and Reports HIV Prevention Through Early Detection and Treatment of Other Sexually Transmitted Diseases United States Recommendations of the Advisory
More informationBreakthroughs and Big Questions: AIDS vaccine research in 2014
Breakthroughs and Big Questions: AIDS vaccine research in 2014 Mary A. Marovich Director, Vaccine Research Program Division of AIDS NIAID/NIH May 19, 2014 1 Future of HIV-1 vaccines is bright Major breakthroughs
More informationCOMMUNICABLE DISEASE
Public Health Activities & Services Inventory Technical Notes COMMUNICABLE DISEASE CLINICAL SERVICES, SURVEILLANCE AND CONTROL In 2014, decision was made to adopt number of national public health activities
More informationAIR FORCE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS
AIR FORCE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS An Air Force addendum to the TRI-SERVICE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS Prepared by: Air Force Institute for Operational Health
More informationThe Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011
The Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011 Section 5: Screening, Treating and Reporting Chlamydia While the information
More informationHIV Prevention Action Coalition (A Workgroup of the Federal AIDS Policy Partnership) Gay Men s Subgroup
HIV Prevention Action Coalition (A Workgroup of the Federal AIDS Policy Partnership) Gay Men s Subgroup COMMUNITY RECOMMENDATIONS TO ADDRESS HEIGHTENED HIV VULNERABILITY AMONG GAY MEN/MSM Policy Recommendation
More informationWOOD COUNTY SCHOOL OF PRACTICAL NURSING. Medical/Surgical Nursing: Reproductive
WOOD COUNTY SCHOOL OF PRACTICAL NURSING Medical/Surgical Nursing: Reproductive Time: 19 Hours Theory; 1 Hour Pharmacology IV, (1 Diet Therapy - Integrated.) Placement: Nursing IV. Instructor: Toni Tennant,
More informationFrequently Asked Questions
Guidelines for Testing and Treatment of Gonorrhea in Ontario, 2013 Frequently Asked Questions Table of Contents Background... 1 Treatment Recommendations... 2 Treatment of Contacts... 4 Administration
More informationHIV New Diagnoses, Treatment and Care in the UK 2015 report
HIV New Diagnoses, Treatment and Care in the UK 2015 report About Public Health England Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities.
More informationHIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016
HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016 Daily emtricitabine/tenofovir (Truvada ) is safe and effective for reducing the risk of HIV acquisition in sexually
More informationFAQs HIV & AIDS. What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease.
HIV & AIDS What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease. What does HIV stand for? Human Immunodeficiency Virus Where did HIV
More informationBasic Presentation HIV/AIDS. For Use by Students, Teachers and the Public Seeking Basic Information About HIV/AIDS
Basic Presentation HIV/AIDS For Use by Students, Teachers and the Public Seeking Basic Information About HIV/AIDS Objectives- Define and understand the difference between HIV Infection and AIDS Describe
More information2014 Naughty or Nice STD/HIV Testing Campaign Hamilton County Public Health
2014 Naughty or Nice STD/HIV Testing Campaign Hamilton County Public Health Background and Research: There is a Syphilis epidemic in Cincinnati and Hamilton County, Ohio. In fact, Cincinnati is ranked
More informationProviding Optimal Care for Your MSM Patients
Providing Optimal Care for Your MSM Patients Medical providers have a critical role to play in improving the health outcomes of Black and Latino men who have sex with men (BLMSM). Studies reinforce the
More informationSIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item 12.3 24 May 2014. Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY WHA67.6 Agenda item 12.3 24 May 2014 Hepatitis The Sixty-seventh World Health Assembly, Having considered the report on hepatitis; 1 Reaffirming resolution WHA63.18,
More informationSTATE OF THE HIV/AIDS EPIDEMIC IN CHARLESTON
STATE OF THE HIV/AIDS EPIDEMIC IN CHARLESTON 12/1/2015 A Crisis Among Lowcountry Youth The Charleston region is facing a serious issue of rising HIV rates, particularly among those under the age of 30.
More informationAAB 2013 Annual Meeting & Educational Conference
American Association of Bioanalysts AAB 2013 Annual Meeting & Educational Conference Occult Hepatitis and HIV Prophylaxis Thursday, May 16, 2013, 9:45 a.m. John H. Hughes, Ph.D. Dept Molecular Virology,
More informationCDC 2015 STD Treatment Guidelines: Update for IHS Providers Sharon Adler M.D., M.P.H.
CDC 2015 STD Treatment Guidelines: Update for IHS Providers Sharon Adler M.D., M.P.H. Clinical Faculty, CA Prevention Training Center Disclosure Information Sharon Adler MD, MPH I have no financial relationships
More informationRoutine HIV Monitoring
Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral
More informationTOWARDS AN HIV VACCINE
why is it so hard to make an HIV vaccine and where are we now? Neal Nathanson, MD Emeritus Professor Department of Microbiology University of Pennsylvania School of Medicine 1 Estimated number of persons
More informationCanine Influenza. What do I need to know?
Canine Influenza What do I need to know? What is canine influenza? Canine influenza is a newly emerging infectious disease caused by a flu virus. In dogs, a highly contagious strain of the influenza A
More informationSexually Transmitted Diseases Treatment Guidelines, 2010
Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Recommendations and Reports December 17, 2010 / Vol. 59 / No. RR-12 Sexually Transmitted Diseases Treatment Guidelines, 2010 department of health
More informationFrequently Asked Questions
Frequently Asked Questions Testing for Gonorrhea Q1: What test should be completed for accurately diagnosing gonorrhea? A1: Testing is done with either a culture or a NAAT (nucleic acid amplification test).
More informationHomeopathy as a treatment for HIV and Aids in Swaziland
Homeopathy as a treatment for HIV and Aids in has been estimated to have the highest infection rateof HIV in the world. The demographics from the Homeopathy project database indicate the following: at
More informationBloodborne Pathogens (HIV, HBV, and HCV) Exposure Management
Bloodborne Pathogens Exposure Policy and Procedures Employees of the State of South Dakota Department of Health Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management PEP Hotline 1-888-448-4911 DOH
More informationSexually Transmitted Infections (STI) One Day Update
Sexually Transmitted Infections (STI) One Day Update February 2015 Overview STI Guideline Changes National STI Services Results Reporting High Transmission Areas: Key Populations STI Guideline Changes
More informationClinical Scenarios CODING AND BILLING 101. Daryn Eikner, Family Planning Council Ann Finn, Ann Finn Consulting
Clinical Scenarios CODING AND BILLING 101 Daryn Eikner, Family Planning Council Ann Finn, Ann Finn Consulting 1 Always remember Follow coding guidelines If you didn t write it down, it didn t happen The
More informationIn Tanzania, ARVs were introduced free-of-charge by the government in 2004 and, by July 2008, almost 170,000 people were receiving the drugs.
ANTIRETROVIRAL TREATMENT What is ART and ARV? ART is a short form for Antiretroviral Therapy (or Treatment). Antiretroviral therapy is a treatment consisting of a combination of drugs which work against
More informationFIGHTING AIDS AT THE GATE
FIGHTING AIDS AT THE GATE T h e r a m p a n t s p r e a d o f H I V i n f e c t i o n a c r o s s t h e g l o b e i s n o l o n g e r t h e m e d i a c r i s i s o f t h e m o m e n t. B u t A I D S h
More informationNATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION (CVJ)
NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION (CVJ) The National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) maximizes public health and safety nationally
More informationAppendix 3 Exposure Incident Report Form
Appendix 3 Exposure Incident Report Form January, 2015 Page 1 of 6 Please see the following pages for the Exposure Incident Report Form. Guidelines for the Management of Exposure to Blood and Body Fluids
More informationSummary of infectious disease epidemiology course
Summary of infectious disease epidemiology course Mads Kamper-Jørgensen Associate professor, University of Copenhagen, maka@sund.ku.dk Public health science 3 December 2013 Slide number 1 Aim Possess knowledge
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationLong Term Socio-Economic Impact of HIV/AIDS on Children and Policy Response in Thailand
Long Term Socio-Economic Impact of HIV/AIDS on Children and Policy Response in Thailand Wattana S. Janjaroen Faculty of Economics and College of Public Health Chulalongkorn University Suwanee Khamman and
More informationOUTLINE POST EXPOSURE PROPHYLAXIS (PEP) OCCUPATIONAL RISK OF VIRAL TRANSMISSION WITH SHARP INJURY FROM INFECTED SOURCE:
Professional needle stick accidents should be dealt with within 48 hours. An ARC (Aids Reference Centre) or an emergency department must be contacted as soon as possible. OUTLINE POST EXPOSURE PROPHYLAXIS
More informationHow To Improve Health Care For An Hiv Patient
The Role of the Nurse Practitioner in HIV Care The Three Bridges Shared Care Model Goals of the HIV Shared Care Program To improve access to primary HIV care for difficult to reach populations To demonstrate
More informationCase Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
More information1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1:
Full-fledged work is in progress towards construction and cloning of codon optimized envelope with subsequent aims towards immunization of mice to study immune responses. 1 2 4 5 6 Figure 4.1: Gel picture
More informationTHE UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH AND SOCIAL WELFARE
THE UNITED REPUBLIC OF TANZANIA Treat for Lymphogranuloma venereum MINISTRY OF HEALTH AND SOCIAL WELFARE Appoint to return after Patient complains of Use Discharge from Continue to 2nd Refer to surgeon
More informationIN THE SENATE OF THE UNITED STATES , 2003. M. introduced the following bill; which was referred to the Committee on A BILL
DRAFT //0 0TH CONGRESS ST SESS. S. To direct the Secretary of Health and Human Services to establish, promote, and support a comprehensive program for education, prevention, and treatment of Hepatitis
More informationhiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants
hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments
More informationAccent on Health Obgyn, PC HERPES Frequently Asked Questions
1. What is herpes? 2. How common is herpes? 3. Is there a cure for herpes? 4. What is oral herpes (cold sores)? 5. How is oral herpes spread? 6. What is genital herpes? 7. How is genital herpes spread?
More informationExpedited Partner Therapy (EPT) for Sexually Transmitted Diseases Protocol for Health Care Providers in Oregon
Expedited Partner Therapy (EPT) for Sexually Transmitted Diseases Protocol for Health Care Providers in Oregon Oregon Health Authority Center for Public Health Practice HIV/STD/TB Section Principles of
More informationVaccines for gastro. the good, the bad, and the remainder. A/Prof Stephen Lambert
Vaccines for gastro the good, the bad, and the remainder A/Prof Stephen Lambert Queensland Children s Medical Research Institute, The University of Queensland & Queensland Children s Health Services Communicable
More informationCore Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* Overview. To change category names: Instructions. 2. Introduce session.
Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* ABOUT THIS ACTIVITY Time: 60 minutes Objectives: By the end of this session, participants will be able to: Reviewed their knowledge of HIV/AIDS
More informationAids Fonds funding for programmes to prevent HIV drug resistance
funding for programmes to prevent HIV drug resistance Call for proposals July 2012 Page 1 van 10 grants@aidsfonds.nl Documentnumber 20120719/JKA/RAP Universal Access Lifting barriers to universal access
More informationGonneke Hermanides, MD Izzy Gerstenbluth, MD epidemiologist
HIV epidemic in the Caribbean Gonneke Hermanides, MD Izzy Gerstenbluth, MD epidemiologist Epi (upon) - demos (people) An epidemic occurs when new cases of a certain disease, in a given human population,
More informationModule 7: The Role of the Nurse
Module 7: The Role of the Nurse Module Objectives To describe the dynamic role of the nurse in the holistic care of a patient receiving ARV treatment To equip nurses with a sense of importance and belief
More informationGuidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis
Guidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
More informationQ and A for PARTNER Studies: Interim analysis results presented at CROI 2014. CROI presentation can be found at www.chip.dk
Q and A for PARTNER Studies: Interim analysis results presented at CROI 2014 STATUS: Results embargoed until 4 March 2014, 18:30 Central European Time (CET). CROI presentation can be found at www.chip.dk
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationSTANDARD PROTOCOL STD AND HIV SCREENING AND EPIDEMIOLOGIC STD TREATMENT
STANDARD PROTOCOL STD AND HIV SCREENING AND EPIDEMIOLOGIC STD TREATMENT RELEASE DATE: REVIEW INTERVAL: YEARLY REVIEW DATE: SITE/SERVICE UNIT: IMPLEMENTATION DATE: REVIEWED BY: CONTACT: APPROVED BY: CONTENTS
More informationPOLICYPOLICY POLICY POLICY MEMBERSHIP MEMBERSHIP MEMBERSHIP MEMBERSHIP MEMBERSHIP MEMBERSHIP MEMBERSHIP MEMBERSHIP MEMBERSHIP MEMBERSHIP MEMBERSHIP
MOBILIZI CON CONN P OTINPROMOT IN IN IN C CONN M NCON SCI CE CE SCIE SCIEN SCIENC E C CON TIN CTIN CONNE C The IAS is the only global, independent and membership based organization of professionals working
More information